59 Y Combinator companies in Diagnostics, with team size, growth, open roles and funding.
Updated weekly, last on November 9, 2026. Roster from Y Combinator's public directory.
| Company | Batch | Team | 6 mo | 12 mo | Open roles | Total raised | Last round |
|---|---|---|---|---|---|---|---|
Redcliffe Labs is India's Largest Omni-channel Diagnostics platform | W21 | 2,065 | +5% | +10% | 0 | $152M | Series C$42M, Sep 2024 |
The genetic testing platform detecting and measuring disease. | S17Public | 866 | +13% | +26% | 21 | $426M | Series D$130M, Jun 2024 |
India's leading on-demand diagnostics company | S20 | 728 | +8% | +8% | 1 | $70.8M | Series C$23.8M, Jun 2026 |
Building Clinical Superintelligence. | S18 | 541 | +20% | +54% | YC | $29.1M | Undisclosed round$7.9M, Apr 2024 |
We make robots for biologists. | W16 | 193 | −1% | −8% | 3 | $260M | Series D$20.1M, Dec 2025 |
Nomic is doing for proteins what Illumina has done for DNA | W20 | 116 | +9% | +13% | YC | $60M | Series B$42M, Sep 2024 |
Blood Test for Early Detection of Ovarian Cancer | S21 | 56 | +2% | +2% | 0 | $24.5M | Grant$17M, May 2026 |
Real-World Data for Health Innovation | W20 | 50 | +9% | +9% | 0 | $20.4M | Series A$10.4M, Sep 2024 |
Diversifying precision cancer diagnostics and treatments | S21 | 49 | −4% | +4% | 0 | $4.4M | Seed$3M, Mar 2022 |
Personalized drug discovery for blood cancer. | W15Public | 29 | +4% | +4% | YC | $57.2M | Series B$189K, Jul 2022 |
Patient Intelligence Platform for Genetic Disease | W19 | 28 | +27% | +4% | 6 | $10.9M | Undisclosed round$10.7M, Nov 2023 |
CRISPR powered Diagnostics with results in minutes. | S21 | 27 | +8% | +8% | 0 | $65M | Series A$25M, Sep 2025 |
Early detection of Alzheimer's disease | S17 | 23 | 0% | +5% | 0 | $14.6M | Undisclosed round$3.5M, Oct 2023 |
Simple tests for complex diseases. | S22 | 21 | +11% | +31% | 0 | $7.5M | Seed$7M, Apr 2025 |
Pioneering Breast Cancer Diagnostics for a Healthier Tomorrow | S21 | 19 | +6% | +6% | 0 | $261K | Seed$136K, Jun 2026 |
Engineering a future without cancer deaths. | S23 | 17 | −6% | YC | $5M | Pre-seed$5M, Sep 2023 | |
AI-enabled automation of diagnostic radiology workflow and reporting. | W20Inactive | 17 | −11% | −11% | 0 | $4.2M | Series A$4.2M, Jun 2021 |
Early, pain-free cancer detection. | W15 | 17 | −15% | −29% | 0 | $5.6M | Seed$4M, May 2018 |
AI enabling digital urine diagnostics in the home | W22 | 16 | +14% | 0 | $13.9M | Undisclosed round$825K, Mar 2026 | |
Brain Longevity | W19 | 16 | +7% | −6% | 0 | $200K | Convertible note$200K, Dec 2021 |
Fast and low-cost diagnostics for real time disease surveillance | W16Inactive | 15 | 0% | 0% | 0 | $3.6M | Angel$33K, Oct 2021 |
One-hour antibiotic sensitivity testing | S21 | 14 | +8% | +17% | 0 | $3.6M | Seed$750K, Aug 2026 |
Cofactor closes the precision medicine gap with predictive diagnostics | S15 | 13 | 0% | +18% | 0 | $28.9M | Undisclosed round$1.2M, Dec 2025 |
At-home diagnostics as a service | W22 | 12 | −14% | YC | SeedMar 2022 | ||
The smart testing platform that unlocks digital health at home. | W22 | 12 | 0% | 0% | 0 | ||
Blood testing device for early diagnosis of cancer and treatment… | W17 | 11 | 0% | −8% | 0 | $2.9M | Seed$204K, Jan 2023 |
AI Powered Animal Diagnostics | W21 | 10 | −23% | −58% | 0 | $4M | Seed$4M, Apr 2021 |
Cancer screening without barriers | X26 | 9 | +29% | +29% | 1 | $500K | YC investment$500K, Jun 2026 |
The API for Diagnostic Test Analysis (COVID-19, FLU, RSV, STD,… | W23 | 8 | −11% | −33% | 0 | $500K | YC investment$500K, Apr 2023 |
Discover drugs that control how much cells "squeeze" to treat disease | W21Inactive | 8 | −20% | −38% | 0 | Undisclosed roundJun 2022 | |
Cancer tests based on whole genome and transcriptome data. | W20 | 8 | 0% | 0% | 0 | $5M | Grant$2M, Apr 2023 |
We built the world's first automated digital pathology lab. | W19 | 8 | +14% | +14% | 0 | $3.2M | Grant$1M, Mar 2021 |
XGenomes is building the sequencing technology of the future. | W19 | 8 | −20% | −20% | 0 | $200K | Grant$200K, Sep 2019 |
Kenota is revolutionizing the way we test for disease | S16Inactive | 8 | 0% | −20% | 0 | $11.1M | Series A$9M, Dec 2020 |
Next-gen blood testing to provide 1000x more data to pharma companies | W18Inactive | 5 | 0% | −17% | 0 | $10.7M | Undisclosed round$9.6M, Oct 2020 |
Rev is a biotechnology company creating better plants. | S17 | 5 | 0% | 0% | YC | $120K | Undisclosed round$120K, Mar 2020 |
At-home blood testing: measure + analyze + enhance. | W17Inactive | 5 | 0% | 0% | 0 | $1.8M | Undisclosed round$1.1M, May 2021 |
The AI scientist for always-on biodefense | S24 | 4 | 0 | $513K | YC investment$500K, Jul 2024 | ||
Higher resolution MRI with faster scan times. | S23 | 4 | 0 | $60K | YC investment$60K, Jul 2023 | ||
Operating systems for biology labs | S18Inactive | 4 | 0 | Non-equity supportDec 2018 | |||
Our tests help eradicate cancer by telling doctors whether they got… | S18 | 4 | −20% | 0 | SeedJan 2025 | ||
Smartphone-enabled, at-home diagnostics | S18Acquired | 4 | 0 | $3.6M | Seed$3.5M, Nov 2019 | ||
Nano-diamonds for cancer detection | S14Inactive | 4 | 0 | $1.7M | Seed$1.7M, Aug 2014 | ||
AI-powered blood test to detect cancer in dogs (and cats soon). | F26 | 3 | 0 | ||||
Semi-Autonomous Diagnostics for Emergent Care | S21 | 2 | 0 | $125K | YC investment$125K, Aug 2021 | ||
A diagnostic lab in a box | S20Acquired | 2 | 0 | $200K | YC investment$125K, Aug 2020 | ||
Finding the right cancer drug for each patient. | S17 | 2 | 0 | $120K | YC investment$120K, Aug 2017 | ||
Personalized prevention using genetics and AI | W24 | 1 | YC | $500K | Seed$500K, Jan 2026 | ||
AI-designed Affinity Reagents | S21 | 1 | 0 | Undisclosed roundAug 2021 | |||
Low-cost blood glucose test strips scanned with a smartphone camera… | W20Inactive | 1 | 0 | $150K | YC investment$150K, Mar 2020 |
Every launched company in YC's public directory, with its batch, status, industry and location. New companies show up the week YC lists them.
Each company is matched to Crustdata by its website. Crustdata adds team size and its change over 6 and 12 months, open roles from job postings, reported funding, and founders' past employers.
Hiring the most counts distinct roles posted in the last 60 days. Growth needs 10+ people today, shrinking 20+ a year ago, so tiny teams do not top the lists. Rebuilt every week.
The numbers on this page come from three Crustdata API calls. Crustdata tags 5,000+ companies with Y Combinator as an investor; swap the filter for any investor, industry or headcount range and track your own list, with founders' work emails one call away.
# 1. every company with Y Combinator as an investor curl https://api.crustdata.com/company/search \ -H "authorization: Bearer $CRUSTDATA_API_KEY" \ -H "x-api-version: 2025-11-01" \ -d '{ "filters": { "field": "funding.investors", "type": "in", "value": ["Y Combinator"] }, "fields": ["basic_info.name", "headcount.total", "headcount.growth_percent", "funding.total_investment_usd"], "limit": 100 }' # 2. open listings per company, last 60 days (limit 0 = counts only) curl https://api.crustdata.com/job/search \ -H "authorization: Bearer $CRUSTDATA_API_KEY" \ -H "x-api-version: 2025-11-01" \ -d '{ "filters": { "op": "and", "conditions": [ { "field": "company.basic_info.company_id", "type": "in", "value": [...] }, { "field": "metadata.date_added", "type": "=>", "value": "2026-08-24" } ]}, "limit": 0, "aggregations": [{ "type": "group_by", "field": "company.basic_info.company_id", "agg": "count" }] }' # 3. the same company filter as a weekly watch: POST /watch/company/search
59 Y Combinator companies are in Diagnostics; 38 are active.
5 companies posted roles in the last 60 days, led by BillionToOne (21 roles), Probably Genetic (6 roles) and Opentrons (3 roles). 11 mark themselves as hiring on YC's directory.
By team growth over 6 months (10+ people): Probably Genetic (+27%), Eden (+20%) and BillionToOne (+13%).
Largest latest rounds in the last 12 months, after their YC batch: Orange Health Labs ($23.8M), Opentrons ($20.1M) and Cofactor Genomics ($1.2M).